ArticleJournal of clinical laboratory analysis2020
Value of circular RNA 0007385 in disease monitoring and prognosis estimation in non-small-cell lung cancer patients.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Circular RNAs in lung cancer: implications for preventing therapeutic resistance.EBioMedicine · 2024Review
- Circ_0007385 promotes the proliferation and inhibits the apoptosis of non-small cell lung cancer cells via miR-337-3p-dependent regulation of LMO3.Histology and histopathology · 2023Article
- Anesthetic propofol suppresses growth and metastasis of lung adenocarcinoma in vitro through downregulating circ-MEMO1-miR-485-3p-NEK4 ceRNA axis.Histology and histopathology · 2022Article
- Role of circular RNAs in the diagnosis, regulation of drug resistance and prognosis of lung cancer.Oncology letters · 2022Review
- Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer.Molecular therapy. Nucleic acids · 2022Review
- CircRNA WHSC1 promotes non-small cell lung cancer progression via sponging microRNA-296-3p and up-regulating expression of AKT serine/threonine kinase 3.Journal of clinical laboratory analysis · 2021Article
- Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives.Frontiers in oncology · 2021Review
- The roles and mechanisms of the circular RNA circ_104640 in early-stage lung adenocarcinoma: a potential diagnostic and therapeutic target.Annals of translational medicine · 2021Article
- Value of circular RNA 0007385 in disease monitoring and prognosis estimation in non-small-cell lung cancer patients.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
- Retracted
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to assess the circular RNA_0007385 (hsa_circ_0007385) expression in tumor/adjacent non-tumor tissues, and the correlation of its tumor expression with clinicopathological features as well as survival in non-small-cell lung cancer (NSCLC) patients.
methods210 NSCLC patients who underwent tumor resection were reviewed in this retrospective study. 210 tumor specimens and 81 paired adjacent specimens were collected, in which the hsa_circ_0007385 expression was detected by reverse transcription-quantitative polymerase chain reaction assay. Disease-free survival (DFS) and overall survival (OS) were recorded, and the last follow-up date was June 30, 2019.
resultsHsa_circ_0007385 was upregulated in tumor tissue compared with adjacent non-tumor tissue (P < .001), and ROC curve analysis revealed that hsa_circ_0007385 expression had an excellent value in distinguishing tumor tissue from adjacent non-tumor tissue with an area under curve of 0.922 (95% CI: 0.890-0.953). Tumor hsa_circ_0007385 high expression correlated with lymph node metastasis (P = .007) and higher TNM stage (P = .004). In addition, DFS (P = .028) and OS (P = .008) were both less favorable in patients with tumor hsa_circ_0007385 high expression compared to patients with tumor hsa_circ_0007385 low expression. Besides, the DFS (P = .008) and OS (P = .012) were also the worst in patients with tumor hsa_circ_0007385 high+++ expression, followed by patients with tumor hsa_circ_0007385 high++ expression and patients with tumor hsa_circ_0007385 high + expression, and the best in patients with tumor hsa_circ_0007385 low expression. Multivariate regression analysis elucidated that tumor hsa_circ_0007385 high expression independently predicted worse OS (P = .033).
conclusionTumor hsa_circ_0007385 could be a novel biomarker for disease monitoring and prognosis prediction in NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.